AstraZeneca Pharma India shares saw a rise after Imfinzi got approval for expanded use. The CDSCO approved it as a first-line treatment for specific endometrial cancer cases. This follows AstraZeneca’s strong Q4 earnings, with a significant jump in net profit and revenue. The company attributes this to its focus on innovation.
Jio Platforms shares jump 5% on Day 2 after ending 27% higher on debut day. Buy, sell or hold?
Jio Platforms shares rose further after a strong market debut, climbing over 32% above the IPO price. Nomura, Motilal Oswal and Elara Capital initiated coverage